Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.

ABSTRACT:

Objective

Carcinosarcoma is a deadly gynecologic malignancy with few effective treatment options. The study of new therapies is difficult because of its rarity. The objective of this study was to determine the efficacy of neratinib in the treatment of HER2 amplified carcinosarcoma.

Methods

The efficacy of neratinib in the treatment of HER2 amplified carcinosarcoma was determined in vitro using seven primary carcinosarcoma cell lines with differential expression of HER2/neu. Data regarding IC50, cell cycle distribution, and cell signaling changes were assessed by flow cytometry. The efficacy of neratinib was determined in treating mice harboring HER2 amplified carcinosarcoma xenografts.

Results

Two of seven (28.5%) carcinosarcoma cell lines were HER2/neu amplified. HER

SUBMITTER: Schwab CL 

PROVIDER: S-EPMC4587290 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature